Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer.

Lung Cancer (Auckl) · 2014 · PMC5217514 · PMID 28210141

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Specifically, a recently presented Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel suggested a positive trend favoring the combination, with ORR of 17%, median PFS more than 4 months, and median OS more than 11 months.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.